SAT-305 EFFECTS OF EMPAGLIFLOZIN VS PLACEBO ON CARDIORENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES AND PROTEINURIC DIABETIC KIDNEY DISEASE: INSIGHTS FROM EMPA-REG OUTCOME
C. Wanner, Sibylle J. Hauske(Heidelberg University), Isabella Zwiener(Boehringer Ingelheim (Germany)), Audrey Koitka‐Weber(Boehringer Ingelheim (Germany)), M. von Eynatten(Boehringer Ingelheim (Germany)), Bernard Zinman(Mount Sinai Hospital)
Cited by 5
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Impaired Fasting Glucose and Impaired Glucose Tolerance
|Diabetes Care|2007|1.4k